US EditionCardiAMP-HF Trial Data Presented for BioCardia Cardiac Cell Therapy for HFrEF - Cardiac Interventions Today
Summary by Cardiac Interventions Today
This story is only covered by news sources that have yet to be evaluated by the independent media monitoring agencies we use to assess the quality and reliability of news outlets on our platform. Learn more here.1 Articles
1 Articles
All
Left
Center
Right
CardiAMP-HF Trial Data Presented for BioCardia Cardiac Cell Therapy for HFrEF - Cardiac Interventions Today
April 7, 2025—BioCardia, Inc. recently announced 2-year outcomes from the double-blind, randomized, placebo-controlled, phase 3 CardiAMP-HF study of the company’s CardiAMP autologous minimally invasive cell therapy for the treatment of patients with ischemic heart failure with reduced ejection fraction. The company stated that the CardiAMP-HF trial included 115 patients enrolled at 18 centers in the United States and Canada. All patients were ma…
Coverage Details
Total News Sources1
Leaning Left0Leaning Right0Center0Last UpdatedBias DistributionNo sources with tracked biases.
Bias Distribution
- There is no tracked Bias information for the sources covering this story.
Factuality
To view factuality data please Upgrade to Premium
Ownership
To view ownership data please Upgrade to Vantage
